BYSI - BeyondSpring Inc

1.47
-0.010   -0.680%

Share volume: 12,147
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$1.48
-0.01
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
23%
Profitability 25%
Dept financing 12%
Liquidity 58%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.38%
1 Month
3.52%
3 Months
-32.57%
6 Months
-21.39%
1 Year
-14.53%
2 Year
-51.00%
Key data
Stock price
$1.47
P/E Ratio 
0.00
DAY RANGE
$1.41 - $1.52
EPS 
-$0.43
52 WEEK RANGE
$0.98 - $3.44
52 WEEK CHANGE
-$15.03
MARKET CAP 
73.001 M
YIELD 
N/A
SHARES OUTSTANDING 
40.332 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$26,162
AVERAGE 30 VOLUME 
$22,822
Company detail
CEO: Lan Huang
Region: US
Website: beyondspringpharma.com
Employees: 80
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Plinabulin, a selective immune-modulating microtubule-binding agent, has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. BeyondSpring Inc. is a clinical stage biopharmaceutical company. Company engages in the development of three small molecule immune agents in preclinical stages; and drug development platform.

Recent news